(Q37851519)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21391897%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

review article

1 reference

title

The use of monoclonal antibodies for the treatment of graft-versus-host disease following allogeneic stem cell transplantation (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21391897%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

1 reference

stem cell transplantation

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21391897%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

author name string

Alessandro Busca

series ordinal

1

1 reference

24 August 2017

language of work or name

English

0 references

publication date

11 March 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21391897%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Biological Therapy

25 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21391897%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21391897%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21391897%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

page(s)

687-697

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21391897%20AND%20SRC:MED&resulttype=core&format=json

National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report

25 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566852

Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566852

Mycophenolate Mofetil in the treatment of acute and chronic GVHD in hematopoietic stem cell transplant patients: four years of experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566852

Sirolimus for treatment of steroid-refractory acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566852

Treatment of severe acute graft-versus-host disease with anti-thymocyte globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566852

Pentostatin in steroid-refractory acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566852

Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566852

A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566852

Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566852

Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566852

Novel strategies for the treatment and diagnosis of graft-versus-host-disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566852

Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566852

Encouraging results with inolimomab (anti-IL-2 receptor) as treatment for refractory acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566852

Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566852

Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566852

CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566852

Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566852

Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566852

A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566852

A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566852

Successful use of Campath-1H in the treatment of steroid refractory liver GvHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566852

Alemtuzumab can successfully treat steroid-refractory acute graft-versus-host disease (aGVHD)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566852

Successful treatment of severe acute intestinal graft-versus-host resistant to systemic and topical steroids with alemtuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566852

Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566852

Alemtuzumab as treatment of steroid-refractory acute graft-versus-host disease: results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566852

Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566852

ATG plus corticosteroid therapy for acute graft-versus-host disease: predictors of response and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566852

Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566852

Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566852

Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566852

A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566852

Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566852

Rituximab for steroid-refractory chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566852

Treatment of refractory chronic GVHD with rituximab: a GITMO study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566852

Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566852

Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566852

Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566852

Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566852

Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.566852

10.1517/14712598.2011.566852

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21391897%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

1 reference